Inflammatory Myofibroblastic Tumor
📧 Sign up to get email alerts when something new happens for Inflammatory Myofibroblastic Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Crizotinib Continuation Clinical Study [Phase 4]
A Phase 4 continuation study of crizotinib sponsored by Pfizer is currently active but not recruiting. The study investigates crizotinib in …
-
CLINICAL_TRIALS trial_result · 2025-12-05Clinical Trial Update: Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors [Phase 1, Phase 2]
A phase 1/2 clinical trial update indicates brigatinib is currently recruiting pediatric and young adult patients with ALK-positive Anaplast…
-
CLINICAL_TRIALS trial_result · 2023-12-11Clinical Trial Update: CREATE: Cross-tumoral Phase 2 With Crizotinib [Phase 2]
Phase 2 cross-tumor trial evaluating crizotinib in multiple locally advanced or metastatic cancers; study completed.
-
FDA approval · 2023-09-07FDA Approved: XALKORI — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XALKORI (crizotinib) from Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS research · 2019-10-21Clinical Trial Update: Ceritinib Rare Indications Study in ALK+ Tumors [Phase 2]
Phase 2 trial update for ceritinib in ALK-altered tumors including anaplastic large cell lymphoma and related conditions; study terminated w…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-03-14Clinical Trial Update: Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors [Phase 2, Phase 3]
Phase 2/3 study of crizotinib in children and adolescents with inflammatory myofibroblastic tumor is underway, status currently unknown.
-
FDA approval · 2018-12-06FDA Approved: XALKORI — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XALKORI (crizotinib) submitted by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS withdrawal · 2017-08-29Clinical Trial Update: Treatment With Crizotinib Single Patient Expanded Access IND 134375
This document reports a single-patient expanded-access use of crizotinib for inflammatory myofibroblastic tumor. The entry is no longer avai…